BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus

Salazar-Camarena, Diana Celeste; Ortiz‐Lazareno, Pablo César; Marín‐Rosales, Miguel; Cruz, Álvaro; Muñoz‐Valle, Francisco; Tapia‐Llanos, Raziel; Orozco‐Barocio, Gerardo; Machado-Contreras, Jesús René; Palafox‐Sánchez, Claudia Azucena

doi:10.1016/j.cyto.2018.11.008

Cited by 28 publications

(17 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, we demonstrated that AF APRIL is significantly associated with SPTD at <34 weeks of gestation after cerclage. In fact, our finding is quite evident, given the association of APRIL with Th1 profile cytokines and the association of aberrant Th1:Th2 profile (activation of the proinflammatory Th1 profile, rather than suppression of the Th2 profile) with preterm labor [25,26].…”

Section: Discussionmentioning

confidence: 63%

Antibody microarray analysis of the amniotic fluid proteome for predicting the outcome of rescue cerclage in patients with cervical insufficiency

et al. 2021

View full text Add to dashboard Cite

Little is known about the biomarkers that can identify patient candidates suitable for rescue cerclage procedure. The purpose of the study was to identify novel biomarkers in amniotic fluid (AF) that can predict the outcome of rescue cerclage in patients with cervical insufficiency by using an antibody microarray. This case-control study was conducted using AF samples collected from singleton pregnant women who underwent rescue cerclage following a diagnosis of cervical insufficiency (19–25 weeks). Patients were divided into case (n=20) and control (n=20) groups based on the occurrence of spontaneous preterm delivery (SPTD) at <34 weeks of gestation after cerclage placement. The AF proteomes were analyzed using an antibody microarray for biomarker discovery work. Ten candidate biomarkers of interest were validated by ELISA. Thirty-one of the molecules studied showed significant intergroup differences (≥ 2-fold change in signal intensity). Validation by ELISA confirmed significantly higher levels of APRIL, S100 A8/A9, TIMP-1, MIP-1α, and IL-8 in women who had SPTD at <34 weeks. Of these, AF S100 A8/A9 and TIMP-1 levels were independent of other potentially confounding factors (e.g., cervical dilatation). S100 A8/A9 had the highest area under the curve at 0.857. Using protein–antibody microarray technology, we identified differentially expressed proteins and several novel biomarkers (APRIL, IL-8, MIP-1α, S100 A8/A9, and TIMP-1) in AF from women who had SPTB at <34 weeks after cerclage for cervical insufficiency. These data can provide an insight into the molecular mechanisms underlying SPTD after rescue cerclage in patients with cervical insufficiency.

show abstract

Section: Discussionmentioning

confidence: 63%

Antibody microarray analysis of the amniotic fluid proteome for predicting the outcome of rescue cerclage in patients with cervical insufficiency

et al. 2021

View full text Add to dashboard Cite

show abstract

“…12 Several lines of evidence reported that inflammatory cytokines destroyed the immunologic balance in lupus, including TNF-α, IL-1β, IL-6 and IL-23. [17][18][19] Patients with SLE reported elevated serum concentration for TNF-α, 16 and TNF-α signalling contributed to lupus development in lupus-prone mice. 20 TNF-α genetic polymorphisms were strongly related to renal disorders, haematological manifestation and elevated prevalence of positive anti-dsDNA antibody in patients with SLE.…”

Section: Discussionmentioning

confidence: 99%

“…Several lines of evidence reported that inflammatory cytokines destroyed the immunologic balance in lupus, including TNF‐α, IL‐1β, IL‐6 and IL‐23 17‐19 . Patients with SLE reported elevated serum concentration for TNF‐α, 16 and TNF‐α signalling contributed to lupus development in lupus‐prone mice 20 .…”

Section: Discussionmentioning

confidence: 99%

IL‐38: A novel cytokine in systemic lupus erythematosus pathogenesis

Liu

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a complex, inflammatory autoimmune disorder. Genetics and environmental factors interacted in occurrence of the disease. It is characterized by dysregulation of autoantibodies, complement system and inflammatory cytokines. 1 Cytokine-mediated immunity has been found to perform significantly in SLE pathogenesis. 2,3 Interleukin-38 (IL-38, previously called IL-1F10) belongs to the IL-1 family and has been identified in recent years. The human IL-38 gene has 4 exons and is located within chromosome 2q13-14.1 near

show abstract

“…Whilst we have focused on B cell-related effects, it is important to recognise that other activities of BAFF and APRIL inhibition, such as influences on plasmacytoid dendritic cells, astrocytes or even T cells, may account for the biological effects of treatment in MS [29][30][31]. Although APRIL targeting agents have been generated [9], they are unlikely to be investigated in MS following the problems recognised with atacicept.…”

Section: Genetic Deletion Of Human Baff-r Can Lead To Arrested B Cellmentioning

confidence: 99%

Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis

Baker

Pryce

James

et al. 2019

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus

Cited by 28 publications

References 85 publications

Antibody microarray analysis of the amniotic fluid proteome for predicting the outcome of rescue cerclage in patients with cervical insufficiency

Antibody microarray analysis of the amniotic fluid proteome for predicting the outcome of rescue cerclage in patients with cervical insufficiency

IL‐38: A novel cytokine in systemic lupus erythematosus pathogenesis

Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis

Contact Info

Product

Resources

About